- Home
- TKLF vs BOLT Comparison
TKLF vs BOLT Comparison
Compare TKLF & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TKLF | BOLT |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 10.5M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TKLF | BOLT |
|---|---|---|
| Price | $2.20 | $4.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 14.2K | ★ 15.6K |
| Earning Date | 12-19-2025 | 03-12-2026 |
| Dividend Yield | ★ 10.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $56.43 |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $2.10 | $0.26 |
| 52 Week High | $4.32 | $7.35 |
Technical Indicators
Market Signals| Indicator | TKLF | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 31.61 | 47.22 |
| Support Level | $2.10 | $4.42 |
| Resistance Level | $3.09 | $5.01 |
| Average True Range (ATR) | 0.15 | 0.32 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 5.68 | 59.89 |
Price Performance
Historical ComparisonAbout TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.